NCT04851769View on ClinicalTrials.gov

Impact of PCSK9 Inhibitors on Coronary Plaque Composition and Vulnerability Assessed by Optical Coherence Tomography

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 2, 2019

Primary Completion Date

January 28, 2021

Study Completion Date

March 1, 2021

Conditions
Randomized Controlled Trials
Interventions
DRUG

PCSK9 inhibitor plus statin

Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).

DRUG

standard statin therapy

Patients will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day.

PROCEDURE

Coronary imaging follow-up

coronary angiography and OCT imaging at week 36 ± 2 weeks follow-up

Trial Locations (1)

100029

Beijing Anzhen Hospital, Beijing

All Listed Sponsors
lead

Beijing Anzhen Hospital

OTHER

NCT04851769 - Impact of PCSK9 Inhibitors on Coronary Plaque Composition and Vulnerability Assessed by Optical Coherence Tomography | Biotech Hunter | Biotech Hunter